PeptidePlaza
From PeptidePlaza, the free peptide reference · 129 compound profiles · Editorial standards
This is the main page. For the full compound index see Contents; for terminology see Glossary.
PeptidePlaza is a free online reference for peptide research — an open encyclopedia of compound profiles and sourced studies. It currently documents 129 compounds across 5 categories. Every factual claim on the site carries a citation to a primary source such as PubMed, PubChem, or the FDA.
The name reflects the core idea: the peptide bond is what links amino acids into a peptide — and a citation is what links a claim to the evidence behind it. Compound entries cover mechanism, sequence, CAS number, half-life, and regulatory status; see Semaglutide for a representative article.
[about]1 Overview
PeptidePlaza organises peptide research into two parts: compound profiles (mechanism, sequence, CAS number, and regulatory status), and studies (peer-reviewed research linked from every profile).
1.1 Coverage
| Section | Entries | Description |
|---|---|---|
| Compound profiles | 129 | Mechanism, chemical data, dosing literature, safety and study index |
| Research guides | 19 | Long-form guides on protocols, mechanisms, and practical handling |
| Glossary | — | Terminology used across compound entries |
1.2 Sourcing and citations
Claims about mechanism, dosing, and safety are attributed to published literature and linked inline. Chemical identifiers are taken from PubChem; regulatory status from the relevant agency. Where evidence is limited or preclinical only, entries say so rather than filling the gap. The full policy is set out in Editorial standards.
[full index]2 Featured compounds
A selection of the most-studied entries. The complete index of 129 compounds is at Contents.
| Compound | Category | Status | Summary |
|---|---|---|---|
| Semaglutide | Metabolic | FDA Approved | A long-acting GLP-1 analog distinguished by its C18 fatty diacid chain, enabling albumin binding and a half-life of ~7 days. One of the most clinically studied peptides in modern metabolic research. |
| Tirzepatide | Metabolic | FDA Approved | A 39-amino acid synthetic peptide that simultaneously activates GIP and GLP-1 receptors. Demonstrated greater weight loss than any approved single-agonist in clinical trials. |
| Retatrutide | Metabolic | Phase 3 | A novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — the first of its kind in human Phase 2 trials. Early data suggests it may surpass dual agonists. |
| MOTS-c | Metabolic | Investigational | A 16-amino acid peptide encoded within the mitochondrial genome — a newly discovered class of signaling molecule. Regulates metabolic homeostasis via AMPK and FOXO1 pathways. |
[all guides]3 Research guides and tools
- Peptide calculator — reconstitution maths: vial strength, BAC water, dose, and syringe units
- Reconstitution guide — sanitising, venting, wall-injection, and storage of reconstituted peptides
4 See also
5 References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine (2021). View source
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (2021). View source
- Stable gastric pentadecapeptide BPC 157 — a review of cytoprotection. PubMed (2016). View source
- GHK-Cu peptide: a review of tissue repair and remodeling. PubMed (2018). View source